MedTrace Logo

Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00761709 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-07-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

AL-39256 Ophthalmic Suspension, 1%

DRUG

Latanoprost Ophthalmic Solution, 0.005%

DRUG

Vehicle

Inactive ingredients used as a placebo comparator

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry, Ph.D. · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-10-31
Completion
2009-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761709 on ClinicalTrials.gov